Cabozantinib is an oral multikinase inhibitor supplied as sixty milligram tablets, marketed under the brands Cometriq and Cabometyx depending on the indication and formulation. It blocks several receptor tyrosine kinases, including MET, VEGFR2, RET, AXL, and KIT, giving it activity across multiple tumor types. For B2B buyers, the relevant questions are supply continuity, storage conditions, and how to select a reliable distributor rather than clinical efficacy claims. Its oral format and established role make it a frequent line item for oncology distributors serving several tumor types. This guide addresses those procurement factors.
By inhibiting MET and VEGFR2, cabozantinib interferes with both tumor cell signaling and the tumor's blood supply, while RET, AXL, and KIT blockade addresses additional resistance-associated pathways. This broad kinase profile distinguishes it from narrowly targeted agents. Procurement teams do not need to revisit the biology at each order, but understanding the multikinase class helps when comparing storage and handling requirements with similar oral oncology products.
Cabozantinib is approved in several oncology settings, including renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, across its capsule and tablet presentations. Buyers should confirm which presentation and indication correspond to their market authorization, because packaging and strength differ between formulations.
As an oral tablet, cabozantinib is stored at controlled room temperature and does not require refrigerated transport, which simplifies cross-border logistics compared with biologics. Stability depends on protecting tablets from moisture, so retain original blister or bottle packaging and avoid humidity-exposed storage. When selecting a distributor, prioritize verifiable Good Manufacturing Practice certification, batch traceability, and documented handling. Engaging a supplier with transparent pricing and a clear chain-of-custody record reduces the risk of rejected shipments at customs and protects product integrity. For recurring supply, negotiate lead times and minimum stock commitments to avoid interruption of continuous therapy, since oral anticancer agents are typically taken on an ongoing schedule. Confirm registration status in the destination market before committing to volume.
Q: Does cabozantinib 60mg require refrigerated shipping? A: No. The tablets are stored at controlled room temperature, though they should be protected from moisture during transit and storage.
Q: What should a distributor provide for compliance? A: Expect GMP certification, batch-level traceability, and clear documentation of storage conditions. Registration in the destination market is also essential.
Q: Why plan minimum stock for this product? A: Continuous oral therapy means gaps in supply can disrupt treatment; negotiated minimum stock and reliable lead times protect patients on an ongoing regimen.
Cabozantinib is an oral multikinase inhibitor supplied as sixty milligram tablets, marketed under the brands Cometriq and Cabometyx depending on the indication and formulation. It blocks several receptor tyrosine kinases, including MET, VEGFR2, RET, AXL, and KIT, giving it activity across multiple tumor types. For B2B buyers, the relevant questions are supply continuity, storage conditions, and how to select a reliable distributor rather than clinical efficacy claims. Its oral format and established role make it a frequent line item for oncology distributors serving several tumor types. This guide addresses those procurement factors.
By inhibiting MET and VEGFR2, cabozantinib interferes with both tumor cell signaling and the tumor's blood supply, while RET, AXL, and KIT blockade addresses additional resistance-associated pathways. This broad kinase profile distinguishes it from narrowly targeted agents. Procurement teams do not need to revisit the biology at each order, but understanding the multikinase class helps when comparing storage and handling requirements with similar oral oncology products.
Cabozantinib is approved in several oncology settings, including renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, across its capsule and tablet presentations. Buyers should confirm which presentation and indication correspond to their market authorization, because packaging and strength differ between formulations.
As an oral tablet, cabozantinib is stored at controlled room temperature and does not require refrigerated transport, which simplifies cross-border logistics compared with biologics. Stability depends on protecting tablets from moisture, so retain original blister or bottle packaging and avoid humidity-exposed storage. When selecting a distributor, prioritize verifiable Good Manufacturing Practice certification, batch traceability, and documented handling. Engaging a supplier with transparent pricing and a clear chain-of-custody record reduces the risk of rejected shipments at customs and protects product integrity. For recurring supply, negotiate lead times and minimum stock commitments to avoid interruption of continuous therapy, since oral anticancer agents are typically taken on an ongoing schedule. Confirm registration status in the destination market before committing to volume.
Q: Does cabozantinib 60mg require refrigerated shipping? A: No. The tablets are stored at controlled room temperature, though they should be protected from moisture during transit and storage.
Q: What should a distributor provide for compliance? A: Expect GMP certification, batch-level traceability, and clear documentation of storage conditions. Registration in the destination market is also essential.
Q: Why plan minimum stock for this product? A: Continuous oral therapy means gaps in supply can disrupt treatment; negotiated minimum stock and reliable lead times protect patients on an ongoing regimen.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
